Retrospective Multicenter Analysis of Malignant Struma Ovarii: Clinical Characteristics, Management, and Outcomes
Authors:
- Atacem Mert AytekinAAAtacem Mert Aytekin
- Yagmur ArslanYAYagmur Arslan
- Utku AkgorUAUtku Akgor
- Murat CengizMCMurat Cengiz
- Banu Boso AslantasBABanu Boso Aslantas
- Huseyin AkilliHAHuseyin Akilli
- Cansu Turker SaricobanCSCansu Turker Saricoban
- Ibrahim YalcinIYIbrahim Yalcin
- Mehmet KefeliMKMehmet Kefeli
- Onur KaraaslanOKOnur Karaaslan
- Dogan VatanseverDVDogan Vatansever
- Ipek Betul Ozcivit ErkanIEIpek Betul Ozcivit Erkan
Open Access
- 12 December 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8807
Abstract
Background/objectives: The study aimed to present cases of malignant struma ovarii from seven centers in Türkiye and evaluate them within the context of the existing literature. Methods: We retrospectively analyzed clinical data from 17 patients treated at seven centers, focusing on clinical features, surgical management, pathology, thyroid function, adjuvant treatment, and outcomes. Additionally, a literature review including eight studies with 178 patients was conducted. Results: The mean age of patients was 44.7 years, with a mean tumor size of 9.2 cm. Elevated Ca 125 was found in 33.3% of patients, while thyroid function abnormalities and hyperthyroidism signs were rare. Pelvic pain and menstrual irregularities were common presenting symptoms. A total of 16 patients (94.1%) had unilateral tumors. Total abdominal hysterectomy with bilateral salpingo-oophorectomy and unilateral salpingo-oophorectomy were the most frequent surgical approaches. Histopathology predominantly showed classical papillary thyroid carcinoma (13 patients, 76%). All patients were FIGO stage I, with no metastasis. Thyroidectomy was performed in seven patients, identifying two concurrent thyroid cancers. Four patients received adjuvant radioactive iodine therapy. During a median follow-up of 43 months, no deaths and one recurrence were observed. The literature review showed a diagnosis age ranging 43–53 years and papillary thyroid carcinoma as the most common subtype. Thyroidectomy and RAI treatment were selectively applied. Among the reported studies, recurrence occurred in 7 of 76 patients (9.2%), while 5-year disease-free and overall survival rates exceeded 94% and 100%, respectively. BRAF mutations were uncommon. Conclusions: Malignant struma ovarii is a rare tumor with a favorable prognosis when diagnosed early and managed appropriately.Keywords
This publication has 32 references indexed in Scilit:
- Neoplasms in Struma Ovarii: A ReviewEndocrine Pathology, 2023
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- 2020 WHO Classification of Female Genital TumorsGeburtshilfe und Frauenheilkunde, 2021
- Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 yearsArchives of Gynecology and Obstetrics, 2021
- Struma ovarii with atypical features and synchronous primary thyroid cancer: a case report and review of the literatureArchives of Gynecology and Obstetrics, 2019
- Pathology of Struma Ovarii: A Report of 96 CasesEndocrine Pathology, 2015
- Severe Ophthalmopathy Developing After Treatment of Coexisting Malignant Struma Ovarii and Graves' DiseaseThyroid®, 2009
- Malignant struma ovarii: A case reportPathology - Research and Practice, 2005
- Cystic Ovarian Metastasis from Papillary Thyroid Carcinoma: A Case ReportThyroid®, 2001
- Struma Ovarii and HyperthyroidismThyroid®, 1999